Hepatitis C virus: from discovery to eradication in 40 years?  by Pawlotsky, J.-M.
Hepatitis C virus: from discovery to eradication in 40 years?
J.-M. Pawlotsky
National Reference Centre for Viral Hepatitis B, C and Delta, Department of Virology, Hoˆpital Henri Mondor, Universite´ Paris-Est and INSERM U955,
Cre´teil, France
E-mail: jean-michel.pawlotsky@hmn.aphp.fr
Article published online: 23 November 2010
Hepatitis C virus (HCV) was discovered in 1989 by Michael
Houghton and coworkers. This discovery represented the
ﬁrst time that a new virus was identiﬁed using exclusively
molecular biology techniques from the blood of an experi-
mentally infected chimpanzee. The development and wide-
spread use of a ﬁrst-generation ELISA assay, and then of
more sensitive enzyme immunoassays and of molecular biol-
ogy-based techniques, for the detection of HCV RNA in
body ﬂuids revealed that HCV was highly prevalent world-
wide and responsible for the vast majority of cases of
so-called non-A, non-B and cryptogenetic chronic hepatitis.
Twenty years later, where are we? In fact, very few medical
ﬁelds have witnessed such rapid progress over such a short
period, as eradication of HCV infection can now be foreseen
within the next 20 years, at least in wealthy countries that
will be able to afford the cost of modern therapies.
Worldwide, almost 200 million individuals are infected
with HCV. Although HCV is ubiquitous, the prevalence of
infection varies from one area to another, as discussed by
Lavanchy in this issue of the journal. HCV most likely origi-
nates from Africa or Asia, where the heterogeneity of HCV
viral strains is greatest. Transmission in other areas of the
world has occurred mostly through blood transfusion, intra-
venous drug use and unsafe medical or surgical procedures.
Blood screening and prevention of viral transmission in intra-
venous drug users have considerably decreased, but not
eradicated, HCV transmission. Therefore, acute cases are
rarely seen nowadays, except in speciﬁc areas of very high
endemicity, such as regions in rural Egypt.
Before the discovery of HCV, Hoofnagle et al. had shown
that interferon (IFN)-a was able to normalize alanine amino-
transferase levels over the long term in patients with chronic
non-A, non-B hepatitis. IFN-a was initially used at a dose of
3 million units three times per week for 6 months. Unfortu-
nately, only 6% of patients receiving such treatment were
able to achieve a sustained virological response (SVR),
deﬁned by undetectable HCV RNA 24 weeks after the end
of therapy. The good news was that, in these patients, infec-
tion was deﬁnitively cured. Extending therapy for an addi-
tional 6 months led to an increase in overall SVR rates to
10%. A major advance in HCV therapy was the introduction
of ribavirin, which, when given in combination with IFN-a,
increases the SVR rates up to 40% overall. The rationale was
that ribavirin is a nucleoside inhibitor that has antiviral activ-
ity against various DNA and RNA viruses. It is now known
that this mechanism is unable to account for the anti-HCV
effect of ribavarin. Ribavirin accelerates the clearance of
infected cells, prevents relapses, and, in patients responding
to IFN-a, transforms an IFN-based antiviral response into
a cure, although the underlying mechanisms remain obscure.
A further advance was the introduction of pegylated forms
of IFN-a that could be administered once weekly, and
increased the global SVR rates up to 50–60% when given in
combination with ribavirin (40–50% SVR in patients infected
with genotype 1, and 80% SVR in those infected with geno-
types 2 and 3).
In the past 10 years, the combination of pegylated IFN-a
and ribavirin has remained the standard of care treatment
for chronic hepatitis C. In addition, the development of sen-
sitive and accurate molecular tools for the monitoring of
HCV therapy, described by Chevaliez in this issue of the
journal, has been particularly helpful in monitoring treatment
efﬁcacy and improving global results by tailoring treatment
duration to the actual on-treatment virological response.
Improvements in the management of side effects and optimi-
zation of adherence have also been beneﬁcial. Nevertheless,
approximately half of the treated patients still failed to eradi-
cate HCV infection, and nothing could be offered to patients
who were non-responsive to a ﬁrst course of pegylated
IFN-a and ribavirin.
Basic research in the HCV ﬁeld has been active and suc-
cessful, thanks to generous funding in most industrialized
countries when the magnitude of the public health problem
became obvious. In vitro models have been developed, such
as cell-free enzyme assays, pseudovirus particles, self-replicat-
ing replicon models and, ultimately, infectious cell culture-
based systems. These models have been particularly useful in
deciphering the molecular mechanisms of the HCV life cycle
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and characterizing the actors involved. These studies have
paved the way to rational antiviral drug design and screening.
Thanks to these efforts, more than 100 anti-HCV molecules
(direct-acting antivirals) are currently at the preclinical or
clinical developmental stage. They are comprehensively
described by Vermehren and Sarrazin in this issue of the
journal. Two potent speciﬁc inhibitors of HCV serine prote-
ase, telaprevir and boceprevir, should soon be available for
use in clinical practice in combination with pegylated IFN-a
and ribavirin in patients infected with HCV genotype 1. The
results of phase III clinical trials with these combinations
have been recently presented. Overall, the SVR rates
are of the order of 65–75% in treatment-naı¨ve patients and,
most importantly, of the order of 50–60% in patients non-
responsive to previous treatment with pegylated IFN-a and
ribavirin. The introduction of these molecules therefore
represents an important step forwards in HCV treatment.
Furthermore, more drugs will become available within the
next few years. Their different targets and modes of action
will allow for creative combination strategies that will hope-
fully increase the cure rates, eventually without IFN-a in a
substantial proportion of cases.
With the advent of such therapies, one can reasonably
envisage that, within the next 15–20 years, the vast majority
of patients with chronic HCV infection (or perhaps all) will
be cured. Currently, the biggest challenge in wealthier areas
of the world is to implement widespread screening and pro-
vide infected individuals with access to curative therapy.
When combined with continued blood screening and public
health initiatives, such screening has the potential to virtually
eradicate HCV infection. It is nevertheless important to
keep in mind that the vast majority of HCV-infected patients
live in areas of the world where access to these expensive
therapies will be denied and viral transmission still occurs at
a high rate. In this context, the only option is the develop-
ment of an effective prophylactic vaccine. Unfortunately,
there has not been much active research in this domain,
and so far it has not been very successful. The development
of an HCV vaccine remains a challenge for the next
20 years.
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